^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | rocilinostat (ACY-1215) (HDAC6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibition of triple-negative breast cancer proliferation and motility by reactivating p53 and inhibiting overactivated Akt
Published date:
12/27/2021
Excerpt:
More importantly, it was observed that combination of ACY‑1215 and ATM inhibitors exhibited markedly more potent antitumor activity than the individual compound in xenograft mouse models of breast cancer with mutant p53. Collectively, our results demonstrated that ACY‑1215 is a novel chemotherapeutic agent that could restore mutant p53 function in cancer cells with strong antitumor activity, either alone or in combination with inhibitors of the ATM protein kinase.
Secondary therapy:
ATM kinase inhibitor
DOI:
10.3892/or.2021.8252
